Table 3. Changes in systolic blood pressure (SBP) with liraglutide versus placebo at the end of 26 weeks by concomitant antihypertensive medication status.

Data are last observation carried forward for the intention-to-treat population.

		n	Least squares mean change (mmHg)	Standard error	P value
Patients receiving concomitant antihypertensive medications
Treatment	Liraglutide 1.2 mg	560	−1.44	0.87	0.0989
	Liraglutide 1.8 mg	884	−2.02	0.78	0.0105
	Placebo	358	+0.61	0.95	0.5187
Estimated treatment differences	Liraglutide 1.2 mg – Placebo		−2.05	0.86	0.0171
	Liraglutide 1.8 mg – Placebo		−2.63	0.80	0.0010
Patients not receiving concomitant antihypertensive medications
Treatment	Liraglutide 1.2 mg	320	−4.42	0.97	<0.0001
	Liraglutide 1.8 mg	467	−4.06	0.86	<0.0001
	Placebo	162	−2.21	1.18	0.0612
Estimated treatment differences	Liraglutide 1.2 mg – Placebo		−2.21	1.21	0.0680
	Liraglutide 1.8 mg – Placebo		−1.85	1.15	0.1058